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ABSTRACT 
The main objective of the present study was to develop a novel 
and stable pioglitazone loaded solid dispersions with enhanced 
solubility and dissolution rate. Different drug-to-carrier ratios were 
prepared by employing hot melt extrusion technique. These 
formulations were characterized for solid state properties by 
differential scanning calorimetry, X-ray powder diffraction and FT-IR 
spectral studies. Formulations were further evaluated for dissolution 
and stability studies. The aqueous solubility of pioglitazone, in 
present formulation was improved by the presence of both the 
polymers. Solid-state characterization indicated pioglitazone was 
present as amorphous material in formulation with Soluplus and 
polyethylene glycol, due to efficient entrapment in polymer matrix. 
The diffraction patterns of solid dispersion indicated the amorphous 
nature of pioglitazone in solid dispersions. The dissolution rate of all 
the solid dispersions was found to be rapid when compared to pure 
pioglitazone. Pioglitazone in pure form has very slow dissolution rate, 
when compared with the solid dispersions. Thus the solid dispersion 
prepared with Soluplus and polyethylene glycol would be useful for 
delivering poorly soluble pioglitazone with enhanced solubility and 
dissolution rate. 
 
Key words: pioglitazone, soluplus, solid dispersions, melt extrusion 
technique. 
 
INTRODUCTION 
With the introduction of combinatorial 
chemistry and high throughput screening, the 
properties of new chemical entities shifted 
towards higher molecular weight and increasing 
lipophilicity that results in decreasing aqueous 
solubility. Thus the drug solubility, absorption, 
sufficient and reproducible bioavailability are 
recognized today as one of the major challenges 
in oral delivery of new drug substances. 
Especially for class II substances, solubility 
enhancement is part of the strategies to 
improve the oral bioavailability (Stegemanna et 
al 2007; Naveen et al 2007). Formulating poorly 
water soluble drug into a dosage form is always 
a challenging task because of the less solubility 
and dissolution concern (Dehghan  et al 2006; 
Christian et al 2000).  A well-established 
method for increasing the solubility and 
bioavailability of poorly water soluble drugs is 
the  solid dispersion technique.  Drugs  in  solid  
dispersion systems can exist in an amorphous 
form in polymeric carriers and such a system 
improves the solubility and dissolution rate of 
the drug compared to the crystalline material 
(Srinivasa Babu  et al 2007).  Solid dispersion 
refers to the dispersion of one or more active 
ingredients in an inert carrier matrix at solid 
state prepared melting (fusion), solvent 
evaporation, solvent wetting, super critical fluid 
technology, lyophilization, melt extrusion etc. 
(Venkatesh  et al 2010; Leuner et al 2000). Many 
of the said approaches were proved to be 
beneficial and produced good results but in few 
cases it lack commerciality because of various 
problems (Abu 1999).  
Hot Melt extrusion technology (HME) is 
the novel technology with an aim to produce 
solid dispersions with lower cost and is 
commercially feasible (Gavin  et al 2009; Singhal  
et al 2011; Breitenbach  2002; Dong  et al 2008; 
Mooter  et al 2008).  
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In this study, solid dispersions were 
prepared by hot melt extrusion method using 
Soluplus as carrier. This method is suitable for 
thermostable drugs and for the polymers that 
possess high melting points or Tg values           
(Bell  1995). Soluplus is a polyvinyl caprolactum 
(57%)-polyvinyl acetate (30%)-poly ethylene 
glycol (PEG 6000-13%) graft co-polymer  
(Linn, et al., 2011). Soluplus shows superior 
performance in forming solid solutions, 
especially in hot melt extrusion processes. PEG 
1500 is used as carrier, solubilizer, absorption 
improvers for active substances usually 
processed in the form of a melt extrusion and 
plasticizer to decrease the processing 
temperature in extruder (Khan et al 1998; 
Verheyen et al 2002). Pioglitazone is a BCS class 
II drug with hypoglycemic action to treat 
diabetes mellitus type 2 (Shahzad et al 2011).  
 
MATERIALS AND METHODS 
Pioglitazone, Soluplus, PEG 1500 were 
obtained as gift samples from Mylan 
Laboratories Ltd, Hyderabad.  All other 
chemicals and reagents used were of analytical 
reagent grade. 
 
Preparation of solid dispersion  
The solid dispersions of pioglitazone 
were prepared by hot melt extrusion technique 
using Soluplus and PEG 1500 as carriers. The 
pioglitazone, soluplus and PEG 1500 were 
weighed accurately in different ratios and 
passed through sieve #40 and blended in 
double cone blender for 10 minutes. These 
blends are then processed in the hot melt 
extruder instrument. The temperatures of the 
heating zones are adjusted in such a manner 
that the drug and the polymer mix well and 
melt well to give a uniform solid dispersion. 
The compositions of various solid dispersions 
were given in table I. 
The melting point of the pioglitazone 
(183-192°C) and the Tg of the Soluplus (70°C) 
were taken into consideration while setting the 
temperatures of the heating zones. 
Temperatures of 60-100-135-150°C (±5-10°C) 
across the four heating zones and an rpm of 
100(±5) was maintained for intense mixing in 
order to obtain uniform and efficient solid 
dispersion. The torque was maintained by 
regulating the feed rate of the blend into the 
screw feeder. The obtained mass is milled by  
using Quadra-co mill and passed through sieve 
No # 60 to obtain uniform fine particles of 
solid dispersions. The obtained solid 
dispersions were subjected to DSC, XRD to 
confirm the conversion of crystalline drug into 
amorphous form and FT IR for drug – carrier 
interaction studies. The drug content, solubility 
studies, dissolution and stability studies were 
carried out for solid dispersion.  
 
Solubility studies 
These studies were performed by taking 
the pioglitazone pure drug and pioglitazone 
solid dispersion equivalent to 30mg of 
pioglitazone and added to 10mL each of 
distilled water and buffer solutions. The 
samples were then subjected to incubated 
shaking at 100rpm for 24h at 36oC. The 
resultant solutions were collected and filtered 
through 0.45µ membrane filters and analyzed 
spectrophotometrically at 269nm after suitable 
dilutions.  
 
Characterization of pioglitazone solid 
dispersions 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry 
measurements were performed on pioglitazone, 
Soluplus, PEG 1500 and solid dispersion 
formulations using differential scanning 
calorimeter (METTLER TOLEDO with eSTAR 
software). The samples were placed in a sealed 
aluminium crucible and evaluated with a heating 
rate of 20ºC/min at a temperature range of 25-
250ºC. The thermograms were recorded and were 
shown in the figures 1 and 2. 
X- Ray Powder Diffraction (XRD) 
The powder crystallinity of the 
pioglitazone and the pioglitazone solid 
dispersions were determined using Bruker D8 
Advance XRD with copper target instrument. 
The conditions were maintained at 40 Kv 
voltages, with 40MA current at room 
temperature. The scanning rate employed was 
0.1°/sec over a range of 2θ values from 3°to 45°. 
The difractograms were shown as figures 3 and 4. 
Fourier Transform Infrared Spectroscopy 
(FTIR) 
The FTIR spectra of pioglitazone, 
Soluplus, PEG 1500 and solid dispersion 
formulations  were  obtained   by  using   Brucker  
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FTIR spectrophotometer to study the interaction 
between  drug  and  carrier   in  solid  dispersions. 
The samples were prepared in KBr discs             
(2mg sample in 200mg KBr) and the sampling 
range was 400-4000 cm-1 and the resolution was 
4cm-1. The FTIR spectra were shown in 5.  
 
Drug content 
Solid dispersions equivalent to 30mg of 
drug were taken and dissolved in methanol and 
filtered using 0.45µ membrane filters. Then the 
filtrate was suitably diluted with buffer           
and drug content was analyzed against blank  
by UV spectrophotometer at 269nm. The 
concentration of drug present in solid 
dispersion is compared with that of standard 
solution containing 30mg of pure drug. The 
percentage of drug present in the solid 
dispersions was calculated with respect to 
standard concentration. 
 
In vitro dissolution studies 
Dissolution rate studies of pure 
pioglitazone and pioglitazone solid dispersions 
were performed in ELECTROLAB 8 stage 
dissolution apparatus with rotating paddles at 
75rpm employing 900mL of pH 2.0 
hydrochloric acid buffer (Marcel Dekker 2004) 
and the temperature was maintained at 
37±0.5°C throughout the experiment. 5mL of 
the samples were withdrawn at various time 
intervals. The absorbance of the samples was 
measured at 269nm for determining the 
amount of drug release at various intervals. 
Each time the equal volume of buffer was 
added for maintaining the constant volume of 
dissolution medium. The dissolution studies 
were carried out in triplicate. Based up on the 
data obtained from the dissolution studies the 
in vitro kinetic modeling parameters such as T 
50, T 90, zero order and first order rate 
constants for solid dispersions were 
determined. The dissolution parameters were 
given in table II. 
 
Data analysis 
Data are expressed as mean ± standard 
deviation, correlation coefficients (R2) and were 
processed using  Microsoft  Office   Excel 2007  
 
 
software. The dissolution profiles of all the 
selected formulations  for  pioglitazone   (SD8) 
were compared with the marketed formulation 
of pioglitazone by using a model independent 
approach of similarity factor, f2, with all time 
points included in the in vitro dissolution studies 
(19). The equation for calculating similarity 
factor is  
N 
f2=50xlog {[1+(1/n) Σ |Rt-Tt |2] - 0.5x100}  
J =1 
Where ‘n’ is the number of dissolution 
time and Rt and Tt are the reference 
(theoretical) and test dissolution values at           
time ‘t’. Dissolution profile was considered 
satisfactory if f2 value lies more than 50. The 
dissolution profiles are considered similar when 
the f2 value is 50 to 100. 
 
Stability studies 
The prepared solid dispersions were 
further subjected to accelerated stability studies 
upto one month at 40°C with 75% RH. The 
samples were withdrawn after one month and 
analyzed by PXRD and FTIR.  
 
RESULTS AND DISCUSSION 
In the present investigation an attempt 
was made to improve the solubility and 
dissolution rate of pioglitazone. The solid 
dispersions of pioglitazone were prepared by 
melt extrusion method using hot melt extruder 
with soluplus alone and in combination with 
PEG 1500 (10%) as carriers. 
 
Solubility measurement 
Initially saturated solubility studies were 
performed for the pioglitazone pure drug and 
also for the solid dispersion by using different 
buffer media. The solubility of pure drug and 
solid dispersions decreased gradually with 
increase in pH which indicated pH dependent 
solubility of the drug. The solubility studies also 
indicated that, the solubility of solid dispersion 
was increased by 16-18 folds at lower pH (1.2 
and 2.0 pH) and 2-8 folds at higher pH (4.5, 
6.8, 7.4 pH) when compared  to that of  pure  
drug.  
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The pure drug pioglitazone and its respective 
solid dispersions have exhibited very high 
solubility in pH 2.0 buffer than the other buffer 
media. The drug content in various solid 
dispersions prepared was estimated 
spectrophotometrically by measuring the 
absorbance at 269 nm. All the solid dispersions 
were found to have excellent entrapment of 
drug in the carrier. The pioglitazone drug 
content in all the dispersions were found to be 
in the range of 97 ± 1.1 to 99.89± 1.3 %. 
 
Characterization of Solid Dispersions. 
The physical state of pioglitazone in the 
solid dispersions was characterized by DSC, 
XRD and FTIR spectral studies. The DSC 
thermograms of pioglitazone alone showed 
endothermic peak at 192-199°C, corresponding 
to its melting point. The DSC thermogram of 
soluplus and PEG1500 (10%) have shown 
endothermic peak at 520C indicating the 
melting point of PEG1500. Slight endothermic 
peak of drug was observed in solid dispersions 
prepared with soluplus alone indicating the 
crystalline nature of drug. No sharp 
endothermic peak of pioglitazone was observed 
in solid dispersions prepared with combination 
of soluplus and PEG1500 (10%) indicating that 
pioglitazone was efficiently dispersed at 
molecular level. However, the peak of PEG 
1500 in those solid dispersions was found to be 
shifted to lower values, indicated the solid–
solid phase transition.  This was further 
supported by XRD. The DSC thermograms of 
pioglitazone and other solid dispersions were 
given as figures 1 and 2.  
The XRD patterns of pioglitazone, 
soluplus, PEG 1500 and solid dispersions were 
shown in figures 3 and 4. The powder 
diffraction patterns of pure pioglitazone 
showed characteristic high diffraction peaks. 
The diffraction patterns of Soluplus showed 
only few peaks with very weak intensities 
indicating the amorphous nature. On the          
other hand the diffraction patterns of           
solid  dispersions  showed  decrease in the peak  
Table I. Compositions of pioglitazone Solid Dispersions (SD) 
 
Formulation code Carrier Ratios Quantity (g) 
SD1 Drug: Soluplus 1:2 10: 20 
SD2 Drug : Soluplus 1:3 10: 30 
SD3 Drug: Soluplus 1:4 10: 40 
SD4 Drug: Soluplus 1:5 10: 50 
SD5 Drug: Soluplus +PEG 1500(10%) 1:2 10: 18+2 
SD6 Drug: Soluplus +PEG 1500(10%) 1:3 10: 27+3 
SD7 Drug: Soluplus +PEG 1500(10%) 1:4 10: 36+4 
SD8 Drug: Soluplus +PEG 1500(10%) 1:5 10: 45+5 
 
Table II. Drug release studies of pioglitazone and SD 8 
 
S. 
No 
SD 
% Drug 
released at 
90 min 
T50 
(min) 
T 90 
(min) 
First Order Rate 
Constant 
K(min-1) 
R2 (First order 
curve) 
1 PD 61.36 ± 0.12 30 >90 0.042 0.920 
2 SD1 70.24± 0.17 28 >90 0.094 0.977 
3 SD 2 76.54± 0.30 24 >90 0.098 0.982 
4 SD 3 80.63± 0.17 18 >90 0.167 0.987 
5 SD 4 100.24± 0.22 16 45 0.181 0.992 
6 SD 5 100.00± 0.24 14 55 0.194 0.987 
7 SD 6 100.00± 0.27 9 35 0.173 0.994 
8 SD 7 100.00± 0.11 8 28 0.183 0.996 
9 SD 8 100.03± 0.13 6 20 0.173 0.997 
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intensity and finally absence of peaks was 
observed in solid dispersions which indicated 
the amorphous nature of pioglitazone in solid 
dispersions and are considered to be the reason 
for the dissolution and solubility enhancement. 
 In order to investigate the possible 
interaction of the drug with carrier FTIR 
analysis was performed. Figure 5 shows the 
FTIR spectra of pure pioglitazone, soluplus and 
pioglitazone solid dispersion (SD8). FTIR 
spectra of pioglitazone showed characteristic 
absorption peaks at 3364 cm–1 (N-H stretching 
amide), 3084 cm–1 (aromatic C-H stretching), 
2928 cm-1 (aliphatic C-H stretching 
asymmetric), 1743 cm-1 (amide C=O 
stretching),  1616 cm-1 (C=C),  1460cm-1 (ring  
C-N stretching), 1242 cm–1 (C-S stretching), 
1084 cm-1 (aliphatic C-O-C) and 850 cm-1 
(para disubstituted aromatic ring). A very broad 
band was observed at 2900 cm-1 that in solid 
dispersion which was due to the presence of 
water molecule. Along with the broad         
peaks from soluplus and PEG 1500 at 3600 cm-
1 and 2900 cm-1 the FTIR spectra of solid 
dispersion still showed the peaks at same 
position of the drug. Hence the FTIR spectrum 
of the solid dispersion is seemed to be only a 
summation   of  drug  and  soluplus   and PEG 1500. 
This indicates that there were no major 
interactions between the functional moieties of 
drug molecule with the excipients incorporated 
in the formulation of solid dispersions.  
 
 
  
Figure 1. DSC Thermograms of Pioglitazone, SD1, 
SD2, SD3, SD4     
 
 
 
Figure 2. DSC Thermograms of Placebo, 
Pioglitazone, PLACEBO, SD5, SD6, SD 
 
 
Figure 3. PXRD data of Drug, Placebo,  SD1, 
SD2,   Placebo, SD5, SD3, SD4. 
 
 
 
Figure 4. PXRD data of Drug, SD6, SD7, 
SD8 
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Dissolution Studies 
The dissolution studies of pioglitazone 
as pure drug and its solid dispersions were 
performed in pH 2.0 hydrochloric acid buffer 
by using USP-II paddle method. Based upon  
the data obtained from the dissolution studies, 
various parameters such as T50, T90, DE30% 
and first order and zero order release rate 
constants were estimated. The dissolution 
parameters such as T50 and T90 were 
measured directly from the dissolution profile 
curves and DE30% was estimated by 
employing trapezoidal rule to the dissolution 
profiles. The first order release rate constant 
was calculated by multiplying the slope value 
obtained from log per cent drug undissolved 
versus time plot with 2.303.   The dissolution 
rate of all the solid dispersions was found to be 
rapid when compared to pure pioglitazone 
(Figure 6 and 7).  The T50, T90 and rate 
constants (K) values of the dispersions 
indicated their rapid drug dissolution than that 
of pure drug. The kinetics of drug release from 
all the solid dispersions follows first order. The 
dissolution profiles of pioglitazone solid 
dispersions were compared with marketed 
tablet formulation of pioglitazone. The 
similarity factors were calculated for these 
formulations. The similarity factor f2 values 
were in the 48 for the solid dispersion. All 
results were calculated as mean± 3 S.D.  
 Solid dispersions prepared by melt 
extrusion method were found to be suitable in 
increasing the dissolution rate of poorly soluble 
drug   pioglitazone.  The  rapid   dissolution  of 
 
 
Figure 5: FTIR data of Drug, Placebo, SD8. 
 
 
 
Fig 6: In vitro dissolution profiles of SD1,  
SD5, SD2, SD3, SD4 & Pioglitazone pure 
pure drug.  drug. Key: ♦ = Pure Drug, ■ = 
SD1, ▲ =SD2, ● = SD3, + = SD4        
 
 
 
Fig 7: In vitro dissolution profiles of SD6, SD7, 
SD8 and Pioglitazone Key: ♦ = Pure Drug, ■ = 
SD5, ▲ = SD6, + = SD7, ● = SD8 
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pioglitazone from solid dispersions may be 
attributed to decrease in crystallinity of drug 
and its molecular and colloidal dispersions in 
hydrophilic carrier. As soluble carrier dissolves, 
the insoluble drug gets exposed to dissolution 
medium in the form of fine particles for quick 
and faster dissolution. It was found that solid 
dispersions containing drug and Soluplus plus 
PEG 1500 in the ratios of 1:5 prepared by melt 
extrusion method has shown faster dissolution 
rates than other dispersions.  
 
Stability Studies 
The solid dispersions (SD8) were further 
evaluated for accelerated stability studies at 
40°C/75% RH for a period of 1 month. 
Pioglitazone found to be present in amorphous 
form in all the three formulations which was 
observed in the FT IR spectra given in figure 8 
were recorded after 1 month. 
Hot melt extrusion process was selected 
to prepare the solid dispersions of pioglitazone. 
Soluplus and PEG 1500 are used as carriers in 
preparing solid dispersions. The purpose of the 
study was to prepare solubility enhanced stable 
solid dispersions of pioglitazone and examines 
the solid-state properties of pioglitazone solid 
dispersions prepared using Soluplus and PEG 
1500 at varying ratios. The solubility studies, 
DSC, XRD and FT IR characterization studies 
revealed that pioglitazone solubility was 
enhanced and it was in an amorphous state and 
uniformly distributed throughout matrix. The 
spectral studies of pioglitazone solid 
dispersions exhibited no changes in the 
principle peaks and all the peaks were observed 
at specific wave numbers as that of their 
respective pure drug. Thus these studies 
indicated that there were no major interactions 
between the functional moieties of drug 
molecule with the excipients incorporated in 
the formulation of solid dispersions.  
The XRD patterns of pioglitazone 
showed sharp peaks indicating the crystalline 
nature of pioglitazone. The diffraction patterns 
of solid dispersion showed decrease in the peak 
intensity or absence of peaks which indicated 
the amorphous nature of pioglitazone in solid 
dispersions. The dissolution studies of 
pioglitazone as pure drug and its solid 
dispersions were performed in pH 2.0 
hydrochloric acid buffer by using paddle 
method. The dissolution rate of all the solid 
dispersions was found to be rapid when 
compared to pure pioglitazone. The T50, T90 
and K values of the dispersions indicated their 
rapid drug dissolution that pure drug. The 
kinetics of drug release from all the solid 
dispersions follows first order. The release 
characteristics of poorly water soluble drug, 
pioglitazone from solid dispersion containing 
Soluplus and PEG 1500 was found to give 
rapid dissolution profiles than their respective 
counterpart. The solubility and dissolution rate 
of pioglitazone in its dispersions form was 
increased due to formation of a matrix with 
 
             
       Figure 8. FTIR Stability data of Drug, Placebo, SD8. 
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Soluplus as a polymer. Soluplus is a polymeric 
solubilizer having amphiphilic chemical 
structure which is widely used for the 
development of solid solutions. Pioglitazone 
solid solutions prepared by Soluplus are capable 
of acting as matrix dispersions with enhanced 
dissolution rate. 
 
CONCLUSION 
The present research showed the 
suitability of Soluplus and PEG 1500 as carriers 
for the preparation of pioglitazone solid 
dispersions by hot melt extrusion process. The 
release characteristics of poorly water soluble 
drug, pioglitazone from solid dispersion 
containing Soluplus and PEG 1500 was found 
to give rapid dissolution profiles than their 
respective counterpart.  Based on the above 
results solid dispersions prepared by hot melt 
extrusion process were found to be ideal for 
improving the dissolution rate and 
bioavailability of poorly soluble drug 
pioglitazone. 
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